Compare CMRE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | INBX |
|---|---|---|
| Founded | 1974 | 2010 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2010 | 2024 |
| Metric | CMRE | INBX |
|---|---|---|
| Price | $15.27 | $110.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 341.2K | 328.0K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $10.84 | $26.19 |
| 52 Week High | $18.06 | $155.29 |
| Indicator | CMRE | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 51.54 |
| Support Level | $13.86 | $70.23 |
| Resistance Level | $15.86 | $131.01 |
| Average True Range (ATR) | 0.46 | 10.16 |
| MACD | -0.04 | -1.30 |
| Stochastic Oscillator | 15.25 | 43.91 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.